<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dopaminergic neuron controls <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> functions such as meso-limbic, striato-nigral and tubero-infundibular systems </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of the present study is the evaluation of the hypothalamic dopaminergic neuron activity in neuro-<z:e sem="disease" ids="C1285162" disease_type="Disease or Syndrome" abbrv="">degenerative disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>alpha-melanocyte-stimulating hormone (alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi>) is synthesized in the arcuate nucleus and lateral part of the hypothalamus, and its secretion is under the inhibitory control of the dopaminergic neuron both in the hypothalamus and pituitary </plain></SENT>
<SENT sid="3" pm="."><plain>alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi>-like-immunoreactivity (alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi>-LI) in CSF is thought to be representative to the dopaminergic neuron activity in the hypothalamus </plain></SENT>
<SENT sid="4" pm="."><plain>We therefore evaluated CSF levels of alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi>-LI in <z:hpo ids='HP_0002503'>spinocerebellar degenerations</z:hpo> and <z:e sem="disease" ids="C0015371" disease_type="Disease or Syndrome" abbrv="">extrapyramidal diseases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The subjects are 11 patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e>, 16 with <z:e sem="disease" ids="C0037019" disease_type="Disease or Syndrome" abbrv="">Shy-Drager syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>), 16 with <z:hpo ids='HP_0008278'>cerebellar cortical atrophy</z:hpo>, 3 with <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e>, 3 with dentato-rubro-pallido-luysian <z:mpath ids='MPATH_127'>atrophy</z:mpath> and 2 with <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> as well as 24 controls </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> were administered <z:chebi fb="0" ids="15765">levodopa</z:chebi> and carbidopa </plain></SENT>
<SENT sid="7" pm="."><plain>CSF was sampled through lumbar puncture in the morning </plain></SENT>
<SENT sid="8" pm="."><plain>After the centrifugation, supernatant of CSF was stored at -40 degrees C until used </plain></SENT>
<SENT sid="9" pm="."><plain>alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi> in CSF was extracted by Rainero's method and measured by RIA </plain></SENT>
<SENT sid="10" pm="."><plain>alpha-<z:chebi fb="6" ids="16768">MSH</z:chebi>-LI levels in control was 23.9 +/- 2.6 pg/ml (mean +/- SD) </plain></SENT>
<SENT sid="11" pm="."><plain>The significant elevation was observed in <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (40.3 +/- 7.5, p less than 0.001) and <z:chebi fb="26" ids="8984">SDS</z:chebi> (42.3 +/- 9.4, p less than 0.001) </plain></SENT>
<SENT sid="12" pm="."><plain>The levels showed not significant correlation with age, duration of illness or severity of <z:e sem="disease" ids="C1145628" disease_type="Disease or Syndrome" abbrv="">autonomic disorder</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Most of other diseases demonstrated the levels within <z:mpath ids='MPATH_458'>normal</z:mpath> range.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>